Skip to main content

Table 1 Characteristics for the patients whose BM samples were tested for BiP levels in CD138+ cells

From: Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

MM code

Age at diagnosis

Ouant Immunoglobulins and Serum immunofixation at collection

Albumin

LDH

Prior Bortezomib?

Myeloma status at time of Collection

MM16

64

lgG 2371, monoclonal protein in gamma region

4.3

201

no

Stable disease

MM17

59

IgG 282, IgA 5083, IgM 16, Two IgA lambda monoclonal band seen, representing 85 %

3.7

106

yes

Stable disease

MM18

68

IgG 2333, IgA 12, 1gM 20, monoclonal protein seen in gamma region

3.3

175

yes

Progression of Disease (increase in M-spike)

MM19

46

IgG 4656, IgA 27, 1 gM 53, monoclonal protein in gamma region

3.8

142

no

Minimal response/stable disease

MM20

unav

IgG 4099, monoclonal band in gamma region

3.7

121

unav

Stable Disease

MM21

56

IgG 314, 1 gM <5, IgA <5, faint free kappa band

4.7

143

yes

Progression of Disease

MM22

52

IgG 453, 1 gM 7, IgA 132, faint IgG lambda band

2.7

170

yes

partial response/stable disease

MM23

70

lgG 840, IgA 9, 1 gM 9, lgG kappa monoclonal spike seen, representing all of monoclonal protein

4.5

564

yes

Remission (very good partial response)

MM24

57

lgG 255, 1 gM 12, IgA 19, faint free Lambda band seen

3.1

154

yes

Progression of Disease

MM25

39

lgG 188, IgA 10, 1gM 12, Free monoclonal lambda light chain, normal Igs greatly diminished

4.7

601

yes

Progression of Disease

MM26

66

lgG 6589, Iga 8, 1 gM <5, lgG kappa monoclonal representing all of total

3.9

166

yes

Progression of Disease

MM27

54

lgG 5543, IgA 11, 1 gM 19, lgG kappa monoclonal protein

4.1

210

yes

Progression of Disease